Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RGS12 | O14924 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923114 | 0.90 | PKM (0.53) | ALOX15PKMKDM4EMEN1KMT2A | |
| SCHEMBL1169765 | 0.88 | L3MBTL1 (0.57) | ALOX15PKMKDM4EMEN1KMT2A | |
| SCHEMBL509956 | 0.85 | PKM (0.59) | ALOX15PKMKDM4EMEN1KMT2A | |
| SCHEMBL7834117 | 0.81 | PKM (0.60) | ALOX15PKMKDM4EMEN1KMT2A | |
| SCHEMBL4933368 | 0.81 | MEN1 (0.68) | KDM4EMEN1KMT2AMGLLALDH1A1 | |
| SCHEMBL6018070 | 0.80 | VNN1 (0.54) | ALOX15PKMKDM4EMEN1KMT2A | |
| SCHEMBL701749 | 0.79 | TAS1R3 (0.56) | PKMMEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL4469796 | 0.77 | MEN1 (0.63) | KDM4EMEN1KMT2AMGLLALDH1A1 | |
| SCHEMBL10573098 | 0.77 | KMT2A (0.57) | ALOX15PKMKDM4EMEN1KMT2A | |
| SCHEMBL27917497 | 0.76 | KDM4E (0.59) | ALOX15KDM4EHTR2AHTR2CCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098215-B2 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | KUREHA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1389460-A1 | CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND | Kureha Chemical Industry Co., Ltd. (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-1273571-A1 | NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME | Kureha Chemical Industry Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | NSUN2, ZC3HAV1L, PNP | ALOX15 3276/4885PKM 2088/4885KDM4E 3110/4885 |
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | CXCR4, CXCR1, CXCR2 | ALOX15 3850/4885PKM 3393/4885KDM4E 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.